RNA respiratory viral infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

Clinical Transplantation

Volumn 33, Issue 9, 2019, Pages

  Manuel, Oriol ^a   Estabrook, Michele ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antibiotic prophylaxis; antibiotic: antiviral; guidelines; infection and infectious agents; viral: influenza

Indexed keywords

ANTIVIRUS AGENT; SIALIDASE INHIBITOR; VIRUS RNA; ANTIINFECTIVE AGENT;

ANTIVIRAL THERAPY; ARTICLE; GRAFT RECIPIENT; HUMAN; HUMAN METAPNEUMOVIRUS; HUMAN METAPNEUMOVIRUS INFECTION; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFLUENZA; INFLUENZA VIRUS; ORGAN TRANSPLANTATION; PARAINFLUENZA VIRUS INFECTION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RHINOVIRUS; RHINOVIRUS INFECTION; RISK FACTOR; VIRAL RESPIRATORY TRACT INFECTION; VIROLOGY; ADVERSE EVENT; ISOLATION AND PURIFICATION; MEDICAL SOCIETY; PRACTICE GUIDELINE; RESPIRATORY TRACT INFECTION; RNA VIRUS;

ANTI-INFECTIVE AGENTS; HUMANS; ORGAN TRANSPLANTATION; PRACTICE GUIDELINES AS TOPIC; RESPIRATORY TRACT INFECTIONS; RNA VIRUSES; SOCIETIES, MEDICAL; TRANSPLANT RECIPIENTS;

EID: 85063326744     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.13511     Document Type: Article

References (99)

1. Manuel O, Estabrook M, AST Infectious Diseases Community of Practice. RNA respiratory viruses in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):212-219.
2. Couch RB, Englund JA, Whimbey E. Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med. 1997;102(3A):2-9; discussion 25-6.
3. López-Medrano F, Aguado JM, Lizasoain M, et al. Clinical implications of respiratory virus infections in solid organ transplant recipients: a prospective study. Transplantation. 2007;84(7):851-856.
4. Peck Aj, Englund Ja, Kuypers J, et al. Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. Blood. 2007;110(5):1681-1688.
5. Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant. 2002;21(5):559-566.
6. Ison MG, Gubareva LV, Atmar RL, Treanor J, Hayden FG. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis. 2006;193(6):760-764.
7. Kumar D, Ferreira VH, Blumberg E, et al. A five-year prospective multi-center evaluation of influenza infection in transplant recipients. Clin Infect Dis. 2018;67:1322-1329.
8. van de Veerdonk FL, Kolwijck E, Lestrade PP, et al. Influenza-associated aspergillosis in critically ill patients. Am J Respir Crit Care Med. 2017;196(4):524-527.
9. Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med. 2004;170(2):181-187.
10. Kumar D, Erdman D, Keshavjee S, et al. Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant. Am J Transplant. 2005;5(8):2031-2036.
11. Peghin M, Hirsch Hh, Len Ó, et al. Epidemiology and immediate indirect effects of respiratory viruses in lung transplant recipients: a 5-year prospective study. Am J Transplant. 2017;17(5):1304-1312.
12. Martin-Gandul C, Mueller NJ, Pascual M, Manuel O. The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation. Am J Transplant. 2015;15(12):3024-3040.
13. Vu DL, Bridevaux PO, Aubert JD, Soccal PM, Kaiser L. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant. 2011;11(5):1071-1078.
14. Ison MG. Respiratory viral infections in transplant recipients. Antivir Ther. 2007;12(4 Pt B):627-638.
15. Danziger-Isakov L, Steinbach WJ, Paulsen G, et al. Multicenter consortium to define the epidemiology and outcomes of pediatric solid organ transplant recipients with inpatient respiratory virus infection. J Pediatric Infect Dis Soc. 2018. [Epub ahead of print].
16. Helantera I, Anttila VJ, Lappalainen M, Lempinen M, Isoniemi H. Outbreak of influenza A(H1N1) in a kidney transplant unit-protective effect of vaccination. Am J Transplant. 2015;15(9):2470-2474.
17. Mahony JB. Detection of respiratory viruses by molecular methods. Clin Microbiol Rev. 2008;21(4):716-747.
18. Nolte Fs, Marshall Dj, Rasberry C, et al. MultiCode-PLx system for multiplexed detection of seventeen respiratory viruses. J Clin Microbiol. 2007;45(9):2779-2786.
19. Mahony J, Chong S, Merante F, et al. Development of a respiratory virus panel test for detection of twenty human respiratory viruses by use of multiplex PCR and a fluid microbead-based assay. J Clin Microbiol. 2007;45(9):2965-2970.
20. Rand KH, Rampersaud H, Houck HJ. Comparison of two multiplex methods for detection of respiratory viruses: FilmArray RP and xTAG RVP. J Clin Microbiol. 2011;49(7):2449-2453.
21. Forman MS, Advani S, Newman C, Gaydos CA, Milstone AM, Valsamakis A. Diagnostic performance of two highly multiplexed respiratory virus assays in a pediatric cohort. J Clin Virol. 2012;55:168-172.
22. Hayden RT, Gu Z, Rodriguez A, et al. Comparison of two broadly multiplexed PCR systems for viral detection in clinical respiratory tract specimens from immunocompromised children. J Clin Virol. 2012;53(4):308-313.
23. Pabbaraju K, Wong S, Tokaryk KL, Fonseca K, Drews SJ. Comparison of the Luminex xTAG respiratory viral panel with xTAG respiratory viral panel fast for diagnosis of respiratory virus infections. J Clin Microbiol. 2011;49(5):1738-1744.
24. Cohen DM, Kline J, May LS, et al. Accurate PCR detection of influenza A/B and respiratory syncytial viruses by use of cepheid xpert Flu+RSV xpress assay in point-of-care settings: comparison to prodesse ProFlu. J Clin Microbiol. 2018;56(2):e01237-17.
25. Miller S, Moayeri M, Wright C, Castro L, Pandori M. Comparison of GeneXpert FluA PCR to direct fluorescent antibody and respiratory viral panel PCR assays for detection of 2009 novel H1N1 influenza virus. J Clin Microbiol. 2010;48(12):4684-4685.
26. Chartrand C, Leeflang MM, Minion J, Brewer T, Pai M. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med. 2012;156(7):500-511.
27. Englund JA, Piedra PA, Jewell A, Patel K, Baxter BB, Whimbey E. Rapid diagnosis of respiratory syncytial virus infections in immunocompromised adults. J Clin Microbiol. 1996;34(7):1649-1653.
28. Roghmann M, Ball K, Erdman D, Lovchik J, Anderson LJ, Edelman R. Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. Bone Marrow Transplant. 2003;32(11):1085-1088.
29. Rovida F, Percivalle E, Zavattoni M, et al. Monoclonal antibodies versus reverse transcription-PCR for detection of respiratory viruses in a patient population with respiratory tract infections admitted to hospital. J Med Virol. 2005;75(2):336-347.
30. Landry ML, Ferguson D. SimulFluor respiratory screen for rapid detection of multiple respiratory viruses in clinical specimens by immunofluorescence staining. J Clin Microbiol. 2000;38(2):708-711.
31. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, et al. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med. 2009;361(7):680-689.
32. Cordero E, Pérez-Romero P, Moreno A, et al. Pandemic influenza A(H1N1) virus infection in solid organ transplant recipients: impact of viral and non-viral co-infection. Clin Microbiol Infect. 2012;18(1):67-73.
33. Kumar D, Michaels MG, Morris MI, et al. Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis. 2010;10(8):521-526.
34. Minnema BJ, Patel M, Rotstein C, et al. Comparison of hospitalized solid organ transplant recipients and nonimmunocompromised patients with pandemic H1N1 infection: a retrospective cohort study. Transplantation. 2011;92(2):230-234.
35. Ng B, Glanville AR, Snell G, et al. The impact of pandemic influenza A H1N1 2009 on Australian lung transplant recipients. Am J Transplant. 2011;11(3):568-574.
36. Kumar D, Blumberg EA, Danziger-Isakov L, et al. Influenza vaccination in the organ transplant recipient: review and summary recommendations. Am J Transplant. 2011;11(10):2020-2030.
37. Manuel O, Pascual M, Hoschler K, et al. Humoral response to the influenza A H1N1/09 monovalent AS03-adjuvanted vaccine in immunocompromised patients. Clin Infect Dis. 2011;52(2):248-256.
38. Schuurmans MM, Tini GM, Dalar L, Fretz G, Benden C, Boehler A. Pandemic 2009 H1N1 influenza virus vaccination in lung transplant recipients: coverage, safety and clinical effectiveness in the Zurich cohort. J Heart Lung Transplant. 2011;30(6):685-690.
39. Hurst FP, Lee JJ, Jindal RM, Agodoa LY, Abbott KC. Outcomes associated with influenza vaccination in the first year after kidney transplantation. Clin J Am Soc Nephrol. 2011;6(5):1192-1197.
40. Kumar D, Cordero E, Blumberg E, et al. A prospective multicenter study of seasonal influenza infection in transplant recipients. Abstract #308. American Transplant Congress; Boston 2012.
41. Chong PP, Handler L, Weber DJ. A systematic review of safety and immunogenicity of influenza vaccination strategies in solid organ transplant recipients. Clin Infect Dis. 2018;66(11):1802-1811.
42. Cordero E, Roca-Oporto C, Bulnes-Ramos A, et al. Two doses of inactivated influenza vaccine improve immune response in solid organ transplant recipients: results of TRANSGRIPE 1–2, a randomized controlled clinical trial. Clin Infect Dis. 2017;64(7):829-838.
43. Natori Y, Shiotsuka M, Slomovic J, et al. A double-blind, randomized trial of high-dose vs standard-dose influenza vaccine in adult solid-organ transplant recipients. Clin Infect Dis. 2018;66(11):1698-1704.
44. Ison M, Skakaly P, Shapira MY, Krivan G, Nist A, Dutkowski R. Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients. Antivir Ther. 2012;17:955-964.
45. Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza –- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(1):1-24.
46. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza –- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(1):1-24.
47. Watanabe A, Chang SC, Kim MJ, Chu DW, Ohashi Y, MARVEL Study Group. Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: A double-blind, randomized, noninferiority clinical trial. Clin Infect Dis. 2010;51(10):1167-1175.
48. Low CY, Kee T, Chan KP, et al. Pandemic (H1N1) 2009 infection in adult solid organ transplant recipients in Singapore. Transplantation. 2010;90(9):1016-1021.
49. Smud A, Nagel CB, Madsen E, et al. Pandemic influenza A/H1N1 virus infection in solid organ transplant recipients: a multicenter study. Transplantation. 2010;90(12):1458-1462.
50. Marty FM, Vidal-Puigserver J, Clark C, et al. Intravenous zanamivir or oral oseltamivir for hospitalised patients with influenza: an international, randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir Med. 2017;5(2):135-146.
51. Ison MG, Fraiz J, Heller B, et al. Intravenous peramivir for treatment of influenza in hospitalized patients. Antivir Ther. 2014;19(4):349-361.
52. Ison MG, Sharma A, Shepard JA, Wain JC, Ginns LC. Outcome of influenza infection managed with oseltamivir in lung transplant recipients. J Heart Lung Transplant. 2008;27(3):282-288.
53. Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir Marboxil for uncomplicated influenza in adults and adolescents. N Engl J Med. 2018;379(10):913-923.
54. Khanna N, Steffen I, Studt J-d, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2009;11(2):100-105.
55. Watcharananan SP, Suwatanapongched T, Wacharawanichkul P, Chantratitaya W, Mavichak V, Mossad SB. Influenza A/H1N1 2009 pneumonia in kidney transplant recipients: characteristics and outcomes following high-dose oseltamivir exposure. Transpl Infect Dis. 2010;12(2):127-131.
56. South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. BMJ. 2013;346:f3039.
57. Lam H, Jeffery J, Sitar DS, Aoki FY. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients. Ther Drug Monit. 2011;33(6):699-704.
58. Ison MG. Antivirals and resistance: influenza virus. Curr Opin Virol. 2011;1(6):563-573.
59. Calatayud L, Lackenby A, Reynolds A, et al. Oseltamivir-resistant pandemic (H1N1) 2009 virus infection in England and Scotland, 2009–2010. Emerg Infect Dis. 2011;17(10):1807-1815.
60. Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, et al. Respiratory syncytial virus seasonality: a global overview. J Infect Dis. 2018;217(9):1356-1364.
61. Paulsen GC, Danziger-Isakov L. Respiratory viral infections in solid organ and hematopoietic stem cell transplantation. Clin Chest Med. 2017;38(4):707-726.
62. Blanchard SS, Gerrek M, Siegel C, Czinn SJ. Significant morbidity associated with RSV infection in immunosuppressed children following liver transplantation: case report and discussion regarding need of routine prophylaxis. Pediatr Transplant. 2006;10(7):826-829.
63. Bridevaux P-O, Aubert J-D, Soccal PM, et al. Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study. Thorax. 2014;69(1):32-38.
64. Flynn JD, Akers WS, Jones M, et al. Treatment of respiratory syncytial virus pneumonia in a lung transplant recipient: case report and review of the literature. Pharmacotherapy. 2004;24(7):932-938.
65. Krinzman S, Basgoz N, Kradin R, et al. Respiratory syncytial virus-associated infections in adult recipients of solid organ transplants. J Heart Lung Transplant. 1998;17(2):202-210.
66. McCurdy LH, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant. 2003;22(7):745-753.
67. Wendt CH. Community respiratory viruses: organ transplant recipients. Am J Med. 1997;102(3A):31-36; discussion 42–3.
68. Siegel JD, Rhinehart E, Jackson J, Chiarello L, Committee at HICPA. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in healthcare settings June 2007; http://www.cdc.gov/ncidod/dhqp/pdf/isolation2007.pdf. Accessed August 31, 2018.
69. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics. 1998;102(3 Pt 1):531-537.
70. Chiu SN, Wang JN, Fu YC, et al. Efficacy of a novel palivizumab prophylaxis protocol for respiratory syncytial virus infection in congenital heart disease: a multicenter study. J Pediatr. 2018;195:108-114.e1.
71. Feltes TF, Cabalka AK, Meissner HCody, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143(4):532-540.
72. Pignotti MS, Carmela Leo M, Pugi A, et al. Consensus conference on the appropriateness of palivizumab prophylaxis in respiratory syncytial virus disease. Pediatr Pulmonol. 2016;51(10):1088-1096.
73. American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415-420.
74. Michaels MG, Fonseca-Aten M, Green M, et al. Respiratory syncytial virus prophylaxis: a survey of pediatric solid organ transplant centers. Pediatr Transplant. 2009;13:451-456.
75. Danziger-Isakov LA, Arslan D, Sweet S, Benden C, Goldfarb S, Wong J. RSV prevention and treatment in pediatric lung transplant patients: a survey of current practices among the International Pediatric Lung Transplant Collaborative. Pediatr Transplant. 2012;16:638-644.
76. Beaird Oe, Freifeld A, Ison Mg, et al. Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. Transpl Infect Dis. 2016;18(2):210-215.
77. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood. 2011;117(10):2755-2763.
78. Glanville AR, Scott A, Morton JM, et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2005;24(12):2114-2119.
79. Pelaez A, Lyon GM, Force SD, et al. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant. 2009;28(1):67-71.
80. Burrows FS, Carlos LM, Benzimra M, et al. Oral ribavirin for respiratory syncytial virus infection after lung transplantation: efficacy and cost-efficiency. J Heart Lung Transplant. 2015;34(7):958-962.
81. Li L, Avery R, Budev M, Mossad S, Danziger-Isakov L. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2012;31(8):839-844.
82. Liu V, Dhillon GS, Weill D. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients. Transpl Infect Dis. 2010;12(1):38-44.
83. Trang TP, Whalen M, Hilts-Horeczko A, Doernberg SB, Liu C. Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: a single-center retrospective cohort study and review of the literature. Transpl Infect Dis. 2018;20(2):e12844.
84. German P, Xin Y, Chien JW, et al. Phase 1 first-in-human, single- and multiple-ascending dose, and food effect studies to assess the safety, tolerability, and pharmacokinetics of presatovir for the treatment of respiratory syncytial virus infection. J Clin Pharmacol. 2018. [Epub ahead of print]. https://doi.org/10.1002/jcph.1112
85. Vilchez RA, Dauber J, McCurry K, Iacono A, Kusne S. Parainfluenza virus infection in adult lung transplant recipients: an emergent clinical syndrome with implications on allograft function. Am J Transplant. 2003;3(2):116-120.
86. Raad I, Abbas J, Whimbey E. Infection control of nosocomial respiratory viral disease in the immunocompromised host. Am J Med. 1997;102(3A):48-52; discussion 3-4.
87. Salvatore M, Satlin MJ, Jacobs SE, et al. DAS181 for treatment of parainfluenza virus infections in hematopoietic stem cell transplant recipients at a single center. Biol Blood Marrow Transplant. 2016;22(5):965-970.
88. Hopkins P, McNeil K, Kermeen F, et al. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med. 2008;178(8):876-881.
89. Larcher C, Geltner C, Fischer H, Nachbaur D, Muller LC, Huemer HP. Human metapneumovirus infection in lung transplant recipients: clinical presentation and epidemiology. J Heart Lung Transplant. 2005;24(11):1891-1901.
90. Shahda S, Carlos WG, Kiel PJ, Khan BA, Hage CA. The human metapneumovirus: a case series and review of the literature. Transpl Infect Dis. 2011;13(3):324-328.
91. Raza K, Ismailjee SB, Crespo M, et al. Successful outcome of human metapneumovirus (hMPV) pneumonia in a lung transplant recipient treated with intravenous ribavirin. J Heart Lung Transplant. 2007;26(8):862-864.
92. Safdar A. Immune modulatory activity of ribavirin for serious human metapneumovirus disease: early i.v. therapy may improve outcomes in immunosuppressed SCT recipients. Bone Marrow Transplant. 2008;41(8):707-708.
93. Ison MG, Hayden FG, Kaiser L, Corey L, Boeckh M. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis. 2003;36(9):1139-1143.
94. Kaiser L, Aubert J-D, Pache J-C, et al. Chronic rhinoviral infection in lung transplant recipients. Am J Respir Crit Care Med. 2006;174(12):1392-1399.
95. van Kraaij M, van Elden L, van Loon AM, et al. Frequent detection of respiratory viruses in adult recipients of stem cell transplants with the use of real-time polymerase chain reaction, compared with viral culture. Clin Infect Dis. 2005;40(5):662-669.
96. DeVincenzo JP, Whitley RJ, Mackman RL, et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med. 2014;371(8):711-722.
97. Simoes EA, DeVincenzo JP, Boeckh M, et al. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis. 2015;211(Suppl 1):S1-S20.
98. McLaughlin LP, Lang H, Williams E, et al. Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes. Cytotherapy. 2016;18(12):1515-1524.
99. Tzannou I, Nicholas SK, Lulla P, et al. Immunologic profiling of human metapneumovirus for the development of targeted immunotherapy. J Infect Dis. 2017;216(6):678-687.